[
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For June 2025",
    "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
    "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748384108,
      "headline": "Best Dividend Aristocrats For June 2025",
      "id": 134736842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173105185/image_2173105185.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
      "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455"
    }
  },
  {
    "ts": null,
    "headline": "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place",
    "summary": "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place",
    "url": "https://finnhub.io/api/news?id=cc007612ccff6c3d3a92a4c004d50f3b0433ec6287a08cca0b137bde8e86d895",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748360877,
      "headline": "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place",
      "id": 134714924,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cc007612ccff6c3d3a92a4c004d50f3b0433ec6287a08cca0b137bde8e86d895"
    }
  },
  {
    "ts": null,
    "headline": "1 Top Dividend Stock to Buy for a Lifetime of Passive Income",
    "summary": "The healthcare leader has a solid and diversified business that can overcome these headwinds.  J&J has increased its dividend for 62 consecutive years.  There are hundreds of dividend stocks on the market, but they don't all offer the same level of security.",
    "url": "https://finnhub.io/api/news?id=f5d1c0970f02aff811fe79e565b22bcbf2023e0471043eba9edbffa4e194b5ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748345400,
      "headline": "1 Top Dividend Stock to Buy for a Lifetime of Passive Income",
      "id": 134715915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The healthcare leader has a solid and diversified business that can overcome these headwinds.  J&J has increased its dividend for 62 consecutive years.  There are hundreds of dividend stocks on the market, but they don't all offer the same level of security.",
      "url": "https://finnhub.io/api/news?id=f5d1c0970f02aff811fe79e565b22bcbf2023e0471043eba9edbffa4e194b5ba"
    }
  },
  {
    "ts": null,
    "headline": "J&J Bankruptcy Filing Dismissed: The Third Time's Not A Charm (Video)",
    "summary": "self In this episode of the Lowenstein Bankruptcy Lowdown, Colleen M. Restel and Eric James Seltzer unpack the dismissal of Johnson &...",
    "url": "https://finnhub.io/api/news?id=6b0b902056a4418b0265577f65d1235aaed4f871f97447764c18078f659befcb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748340675,
      "headline": "J&J Bankruptcy Filing Dismissed: The Third Time's Not A Charm (Video)",
      "id": 134708839,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "self In this episode of the Lowenstein Bankruptcy Lowdown, Colleen M. Restel and Eric James Seltzer unpack the dismissal of Johnson &...",
      "url": "https://finnhub.io/api/news?id=6b0b902056a4418b0265577f65d1235aaed4f871f97447764c18078f659befcb"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Income Stock Fund Q1 2025 Commentary",
    "summary": "BNY Mellon Income Stock Fund (Class A at NAV) returned 3.11% during the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=daa65f5c3dbc517f6c21c1e66b32a2b50aec8c1b7dc22bd14c2abe6bbb05afde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748340060,
      "headline": "BNY Mellon Income Stock Fund Q1 2025 Commentary",
      "id": 134708851,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1881807987/image_1881807987.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Income Stock Fund (Class A at NAV) returned 3.11% during the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=daa65f5c3dbc517f6c21c1e66b32a2b50aec8c1b7dc22bd14c2abe6bbb05afde"
    }
  },
  {
    "ts": null,
    "headline": "Johnson &amp; Johnson: Dividend King On Sale Yielding Over 3% And Undervalued",
    "summary": "JNJ offers a 62-year dividend growth streak, undervalued stock, and double-digit EPS growth.",
    "url": "https://finnhub.io/api/news?id=74b042315eef62f6a5ff862d993dbe9d944dc2a3e1d6acc38b8bf934ba0f49db",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748334600,
      "headline": "Johnson &amp; Johnson: Dividend King On Sale Yielding Over 3% And Undervalued",
      "id": 134708282,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "JNJ offers a 62-year dividend growth streak, undervalued stock, and double-digit EPS growth.",
      "url": "https://finnhub.io/api/news?id=74b042315eef62f6a5ff862d993dbe9d944dc2a3e1d6acc38b8bf934ba0f49db"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth",
    "summary": "Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth",
    "url": "https://finnhub.io/api/news?id=ea31cf14cb95e9cc58cc2f1b41c5393120af5171edd1bcc50afc2c44b6d2e5b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748324364,
      "headline": "Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth",
      "id": 134707088,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ea31cf14cb95e9cc58cc2f1b41c5393120af5171edd1bcc50afc2c44b6d2e5b7"
    }
  }
]